1. Medtech Insight
  2. >>Business
  3. >>Investor Eye

Exec Chat: 'Wow Factor' Is Important in Medtech Investment, But It’s Not Everything Says Ceros CEO

'There is a Revolution In Medtech And Money On the Sidelines,’ Ceros’ Mark Goldwasser told Medtech Insight in an interview

 
• By Marion Webb

Medtech Insight interviewed the CEO of Ceros Financial Services and its investment banking division, Ceros Capital Markets, about the firm’s considerations for funding early-stage medtechs, and outlook for medtech fundraising, in this uncertain economic climate.

Mark Goldwasser
• Source: Ceros Financial Services

Mark Goldwasser, CEO of New York-based asset management firm Ceros Financial Services, thinks there is a revolution starting in the medtech industry, money on the sidelines, and opportunities to be had in this post-Covid world.

Goldwasser recently talked to Medtech Insight about the company’s investment portfolio and outlook for medtech investment, which has been facing...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Investor Eye

Disparities — Including Financial Shortcomings — Remain In Women’s Health, Execs Say

 
• By Brian Bossetta

FemTech leaders discussed some of the barriers that remain in unlocking the full potential of the women’s health market during SiS New York last week. They also offered solutions.

LSX Europe: Women’s Health Education Is The Key For Unlocking VC Investment

 
• By Natasha Barrow

Flo Health was the first femtech unicorn to be valued at over $1bn. But the company faced 49 investment rejections before reaching that status, Anna Klepchukova, the company’s chief medical officer, told the LSX World Congress Europe. THENA Capital’s Esther Reynal de St Michel Richardot talked through the firm’s gender-smart investment strategy.

Anglonordic 25: Women’s Health Needs Therapeutic Success To Encourage Wider Investment

 
• By Natasha Barrow

Health tech is at the forefront of the women's health sector, securing 38% of venture capital in 2024. However, panelists at the Anglonordic Life Science Conference held 3 April asserted that a successful therapeutic breakthrough is key to gaining investor confidence and accelerating venture capital.

Investor Eye: Sofinnova Partners Are Redefining And Disobeying The Venture Investment Commandments

 
• By Barnaby Pickering

Sofinnova Partners has played an important role in defining the medtech investment space for the past 50 years, helping bring to market a plethora of life-saving technologies, even when they appear, initially, to be risky.

More from Business

J&J MedTech Launches KINCISE 2 Surgical Automated System In US

 
• By Natasha Barrow

The KINCISE 2 Surgical Automated System aims to “reduce the physical burden on surgeons compared to manual impaction in primary and revision hip and revision knee replacement procedures,” said J&J MedTech.

Johnson & Johnson MedTech: How To Scale Digital Solutions

 
• By Natasha Barrow

J&J's EMEA head of digital solutions, Julia Fishman, talks about the major hurdles in scaling digital innovation, tips for clinical adoption and what’s up next on J&J’s innovation road map. Robot-assisted surgery pioneer Ivo Broeders gives his perspective on the difficulties in clinical adoption.

Quest Diagnostics Minimizes China Tariff Risk With Less Than 1% Supply Chain Exposure

 
• By Shubham Singh

Quest reaffirmed its full-year guidance despite macroeconomic concerns and tariff uncertainty. Revenues are expected between $10.7bn and $10.85bn. Adjusted earnings per share (EPS) is estimated in the $9.55 to $9.80 range for the full year, with EPS between $8.62 and $8.87.